<DOC>
	<DOCNO>NCT01147692</DOCNO>
	<brief_summary>This open-label study evaluate pharmacokinetics simvastatin coadministered albiglutide healthy adult subject . The primary objective ass effect albiglutide dose pharmacokinetics simvastatin .</brief_summary>
	<brief_title>A Drug Interaction Study Simvastatin Albiglutide</brief_title>
	<detailed_description>This Phase I open-label study evaluate pharmacokinetics simvastatin coadministered albiglutide healthy adult subject . The primary objective ass effect albiglutide dose pharmacokinetics simvastatin .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>clinically significant disease clinically significant abnormal laboratory value female must nonchildbearing potential body mass index ( BMI ) &gt; /=18 kg â‰¤30 kg/m2 nonsmoker negative drug screen positive test result hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) clinically relevant abnormality female subject pregnant breastfeed history anaphylactic reaction drug history significant cardiovascular pulmonary dysfunction current chronic history liver disease history alcohol substance abuse history thyroid dysfunction disease history gastrointestinal surgery disease history pancreatitis previously receive GLP1 mimetic compound ( e.g. , exenatide )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>albiglutide</keyword>
	<keyword>simvastatin</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>